CheckMate 511: 3-Year Follow-up of 2 Different Dosing Regimens of Nivolumab + Ipilimumab for Patients With Advanced Melanoma

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
Three-year follow-up of CheckMate 511 shows continued improved safety and comparable efficacy of NIVO3 + IPI1 vs NIVO1 + IPI3 for patients with advanced melanoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 461 KB
Released: June 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings